| 0 (0%) | 02-21 18:46 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 25.11 | 1-year : | 26.02 |
| Resists | First : | 21.5 | Second : | 22.28 |
| Pivot price | 20.86  |
|||
| Supports | First : | 20.23 | Second : | 16.83 |
| MAs | MA(5) : | 20.82 |
MA(20) : | 20.96 |
| MA(100) : | 21.11  |
MA(250) : | 19.2 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 32 |
D(3) : | 42.4 |
| RSI | RSI(14): 41 |
|||
| 52-week | High : | 23.62 | Low : | 15.51 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HEP ] has closed above bottom band by 8.4%. Bollinger Bands are 49.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 20.86 - 21.03 | 21.03 - 21.15 |
| Low: | 19.98 - 20.16 | 20.16 - 20.29 |
| Close: | 20.21 - 20.49 | 20.49 - 20.69 |
Fri, 20 Feb 2026
3 Plus Your Home- HEP - Local 3 News
Wed, 18 Feb 2026
Newborn hepatitis B vaccination rates decline over recent years - centraloregondaily.com
Mon, 16 Feb 2026
U.S.-Funded Hepatitis B Vaccine Trial Continues to Draw Criticism - hepmag.com
Mon, 16 Feb 2026
WHO criticizes CDC-funded vaccine study in Africa as unethical - CIDRAP
Fri, 13 Feb 2026
Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau - World Health Organization (WHO)
Thu, 12 Feb 2026
House approves bill to make hepatitis B vaccine no longer required in New Hampshire - New Hampshire Bulletin
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 126 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 63.9 (%) |
| Held by Institutions | 26.3 (%) |
| Shares Short | 1,650 (K) |
| Shares Short P.Month | 1,550 (K) |
| EPS | 1.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.09 |
| Profit Margin | 40.9 % |
| Operating Margin | 45.4 % |
| Return on Assets (ttm) | 5.7 % |
| Return on Equity (ttm) | 25 % |
| Qtrly Rev. Growth | 6.3 % |
| Gross Profit (p.s.) | 2.66 |
| Sales Per Share | 4.61 |
| EBITDA (p.s.) | 2.77 |
| Qtrly Earnings Growth | 50.2 % |
| Operating Cash Flow | 351 (M) |
| Levered Free Cash Flow | 167 (M) |
| PE Ratio | 10.76 |
| PEG Ratio | -9.1 |
| Price to Book value | 2.88 |
| Price to Sales | 4.42 |
| Price to Cash Flow | 7.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|